4 transcripts
SDGR
Earnings call transcript
NASDAQ
2024 Q2
31 Jul 24
in cancer cells termed synthetic lethality. This profile allows us to implement an intermittent dosing schedule with the goal of maintaining efficacy
SDGR
Earnings call transcript
NASDAQ
2024 Q1
1 May 24
you, Karen. As you heard, we are off to an excellent start this year and are continuing to make progress against our goals for the year. We appreciate
SDGR
Earnings call transcript
NASDAQ
2023 Q4
28 Feb 24
and materials are discovered, and I'm incredibly proud of the progress we have made toward achieving this goal. There has been turbulence in the global
SDGR
Earnings call transcript
NASDAQ
2023 Q2
2 Aug 23
, the joint team has made substantial progress towards the technical goals for this complex target. The program is now wholly-owned by Schrödinger
- Prev
- 1
- Next